{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:26:51Z","timestamp":1794360411298,"version":"4.9.0"},"reference-count":27,"publisher":"Medical Association of Nippon Medical School","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2021,12,25]]},"DOI":"10.1272\/jnms.jnms.2021_88-517","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T22:09:15Z","timestamp":1640729355000},"page":"569-573","source":"Crossref","is-referenced-by-count":10,"title":["A Case of Autoimmune Hepatitis\/Primary Biliary Cholangitis Overlap Syndrome during Treatment with Brodalumab for Generalized Pustular Psoriasis"],"prefix":"10.1272","volume":"88","author":[{"given":"Shizuka","family":"Okazaki","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Hoashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jensen P, Egeberg A, Gislason G, Hansen PR, Thyssen JP, Skov L. Increased risk of autoimmune hepatitis in patients with psoriasis: A Danish nationwide cohort study. J Invest Dermatol. 2016 Jul;136 (7):1515-7.","DOI":"10.1016\/j.jid.2016.02.812"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology. 2000 May;31 (5):1055-60.","DOI":"10.1053\/he.2000.7050"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Zhang W, De D, Mohammed KA, et al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun. 2018 Mar;2 (3):245-53.","DOI":"10.1002\/hep4.1148"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Efe C, Wahlin S, Ozaslan E, et al. Autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol. 2012 May;24 (5):531-4.","DOI":"10.1097\/MEG.0b013e328350f95b"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Angulo JM, Sigal LH, Espinoza LR. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin Arthritis Rheum. 1998 Dec;28 (3):187-92.","DOI":"10.1016\/S0049-0172(98)80035-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Naiyanetr P, Butler JD, Meng L, et al. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J Autoimmun. 2011 Nov;37 (3):209-16.","DOI":"10.1016\/j.jaut.2011.06.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nakayama S, Murashima N. Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin. Indian J Gastroenterol. 2011 Mar;30 (2):97-9.","DOI":"10.1007\/s12664-011-0092-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Goujon C, Dahel K, B\u00e9rard F, Guillot I, Gunera-Saad N, Nicolas JF. Autoimmune hepatitis in two psoriasis patients treated with inflixmab. J Am Acad Dermatol. 2010 Aug;63 (2):e43-4.","DOI":"10.1016\/j.jaad.2009.02.029"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: A review. J Clin Transl Hepatol. 2018 Dec 28;6 (4):402-9.","DOI":"10.14218\/JCTH.2018.00039"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sisman G, Erzin Y, Bal K. Primary biliary cirrhosis developing in a patient with Crohn&apos;s disease during the course of infliximab treatment: the first case in the literature. J Crohns Colitis. 2013 Oct;7 (9):e397-8.","DOI":"10.1016\/j.crohns.2013.03.003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Serizawa N, Hoashi T, Saeki H, Kanda N. A case of autoimmune hepatitis during treatment with brodalumab for psoriasis. J Nippon Md Sch. 2020;87 (6):359-61.","DOI":"10.1272\/jnms.JNMS.2020_87-607"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018 Nov;45 (11):1235-70.","DOI":"10.1111\/1346-8138.14523"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yang CY, Ma X, Tsuneyama K, et al. IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology. 2014 May;59 (5):1944-53.","DOI":"10.1002\/hep.26979"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bovensiepen CS, Schakat M, Sebode M, et al. TNF-producing Th1 cells are selectively expanded in liver infiltrates of patients with autoimmune hepatitis. J Immunol. 2019 Dec 15;203 (12):3148-56.","DOI":"10.4049\/jimmunol.1900124"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Beringer A, Miossec P. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmun Rev. 2018 Dec;17 (12):1176-85.","DOI":"10.1016\/j.autrev.2018.06.008"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rong G, Zhou Y, Xiong Y, et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol. 2009 May;156 (2):217-25.","DOI":"10.1111\/j.1365-2249.2009.03898.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yaffee HS. Trauma and pustular psoriasis. J Am Acad Dermatol. 1985 Dec;13 (6):1055-7.","DOI":"10.1016\/S0190-9622(85)80500-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yang J, Yu YL, Jin Y, Zhang Y, Zheng CQ. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J Gastroenterol. 2016 Sep 7;22 (33):7579-86.","DOI":"10.3748\/wjg.v22.i33.7579"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci. 2015 Dec 24;17 (1):14.","DOI":"10.3390\/ijms17010014"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001 Dec 15;167 (12):6821-6.","DOI":"10.4049\/jimmunol.167.12.6821"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lopetuso LR, Mocci G, Marzo M, et al. Harmful effects and potential benefits of anti-tumor necrosis factor (TNF) -\u03b1 on the liver. Int J Mol Sci. 2018 Jul 27;19 (8):2199.","DOI":"10.3390\/ijms19082199"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30 (2):239-45.","DOI":"10.1038\/clpt.1981.154"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Schwarzenberger P, Huang W, Ye P, et al. Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol. 2000 May 1;164 (9):4783-9.","DOI":"10.4049\/jimmunol.164.9.4783"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Monteleone G, Pallone F, Macdonald TT. Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev. 2010 Dec;21 (6):471-5.","DOI":"10.1016\/j.cytogfr.2010.05.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sarra M, Cupi ML, Bernardini R, et al. IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism. Hepatology. 2013 Oct;58 (4):1436-50.","DOI":"10.1002\/hep.26446"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. O&apos;Connor W Jr, Zenewicz LA, Flavell RA. The dual nature of T (H) 17 cells: shifting the focus to function. Nat Immunol. 2010 Jun;11 (6):471-6.","DOI":"10.1038\/ni.1882"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tosello Boari J, Amezcua Vesely MC, Bermejo DA, et al. IL-17RA signaling reduces inflammation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils. PLoS Pathog [Internet]. 2012;8 (4):e1002658. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22577359","DOI":"10.1371\/journal.ppat.1002658"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/88\/6\/88_JNMS.2021_88-517\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T04:06:46Z","timestamp":1641010006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/88\/6\/88_JNMS.2021_88-517\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,25]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2021_88-517","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,25]]},"article-number":"JNMS.2021_88-517"}}